Wells Fargo & Company Avadel Pharmaceuticals PLC Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$12.55 - $17.22 $303,710 - $416,724	-24,200 Reduced 58.17%	17,400 $293,000
Q4 2023 Feb 09, 2024	BUY	$9.64 - $14.59 $234,396 - $354,755	24,315 Added 140.67%	41,600 $587,000
Q3 2023 Nov 13, 2023	SELL	$10.3 - $15.99 $131,994 - $204,911	-12,815 Reduced 42.57%	17,285 $178,000
Q2 2023 Aug 15, 2023	BUY	$8.48 - $16.48 $123,808 - $240,608	14,600 Added 94.19%	30,100 $496,000
Q1 2023 May 12, 2023	BUY	$6.41 - $9.95 $44,870 - $69,650	7,000 Added 82.35%	15,500 $141,000
Q4 2022 Feb 13, 2023	SELL	$5.02 - $10.0 $15,085 - $30,050	-3,005 Reduced 26.12%	8,500 $60,000
Q3 2022 Nov 14, 2022	SELL	$2.57 - $7.31 $244 - $694	-95 Reduced 0.82%	11,505 $58,000
Q2 2022 Aug 12, 2022	BUY	$1.07 - $6.95 $1,070 - $6,950	1,000 Added 9.43%	11,600 $28,000
Q1 2022 May 16, 2022	SELL	$5.46 - $8.29 $444,171 - $674,391	-81,350 Reduced 88.47%	10,600 $72,000
Q4 2021 Feb 14, 2022	SELL	$7.34 - $11.18 $492,147 - $749,619	-67,050 Reduced 42.17%	91,950 $743,000
Q3 2021 Nov 15, 2021	SELL	$6.49 - $9.91 $363,115 - $554,464	-55,950 Reduced 26.03%	159,000 $1.56 Million
Q2 2021 Aug 16, 2021	BUY	$6.73 - $9.05 $19,853 - $26,697	2,950 Added 1.39%	214,950 $1.45 Million
Q1 2021 May 13, 2021	BUY	$6.61 - $10.07 $1.24 Million - $1.89 Million	187,731 Added 773.54%	212,000 $1.92 Million
Q4 2020 Feb 09, 2021	BUY	$5.03 - $7.95 $79,021 - $124,894	15,710 Added 183.55%	24,269 $162,000
Q3 2020 Nov 05, 2020	BUY	$5.02 - $8.98 $9,081 - $16,244	1,809 Added 26.8%	8,559 $43,000
Q2 2020 Aug 13, 2020	BUY	$7.25 - $11.75 $33,792 - $54,766	4,661 Added 223.12%	6,750 $55,000
Q1 2020 May 14, 2020	BUY	$4.06 - $10.64 $8,481 - $22,226	2,089 New	2,089 $17,000

Others Institutions Holding AVDL

# of Institutions

Shares Held

1.07M

Call Options Held

Put Options Held

View Full List

About AVADEL PHARMACEUTICALS PLC

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $661M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

More about AVDL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account